Asuragen, Inc.’s Xpansion Interpreter® Test Study Of 1,040 Transmissions Of Fragile X Alleles Reveals Personalized Risks For Expansion From Parent To Child

AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., announced today a collaborative publication with scientists at the New York Institute for Basic Research in Developmental Disabilities that describes the most comprehensive study to date examining the relationship between AGG sequence interruptions and the risk of triplet repeat expansion in the fragile X gene, FMR1. The publication, titled "Fragile X Full Mutation Expansions are Inhibited by One or More AGG Interruptions in Premutation Carriers" assessed 1,040 parent-to-child transmissions of intermediate and premutation-sized fragile X alleles from 705 families and is available online in Genetics in Medicine, a leading translational genetics journal published by the American College of Medical Genetics. The FMR1 molecular analyses reported in the study were enabled using a fragile X technology pioneered by Asuragen and commercialized as Xpansion Interpreter® in the company’s CAP-accredited CLIA laboratory.

Help employers find you! Check out all the jobs and post your resume.